IMF's Nurse Leadership Board Issues White Paper on Continuous Treatment with Velcade

The IMF's Nurse Leadership Board (NLB) has authored a white paper on the use of Velcade (bortezomib) in continuous treatment regimens for myeloma. The report was developed at the 2014 Nurse Leadership Board Roundtable Meeting, held in Anaheim, California in April 2014. The white paper reviews the latest clinical data on continuous treatment with Velcade, discusses continuous treatment and management of treatment fatigue, and defines responsibilities of nurses during continuous treatment.
Source: International Myeloma Foundation - Category: Hematology Source Type: news